Abstract: Endometrial carcinoma (EC) is the most widespread gynecologic malignancy and occupies
Our results showed that expression of p53 in endometrium patientsaccording stage was non-significant difference (P>0.05), while intensity was appeared a highly significant difference (p=0.008). Results of [14] showed that 7 out of 27 cases had positive expression in the low stage (stage I and II) of endometrial cancer, while in thestage(III and IV )only 10cases out of the 23cases had p53-postive endometrial cancer .Moreover, [15] found in theendometriod adenocarcinomas, stage IB 5 (13.9%)out of 36 caseshad p53-postive , in stage IIIC 4 (80.0%)out of 5 cases had p53 positive. Whileserous papillary endometrial adenocarcinomas,stage IB showed 2(100.0%) had positive,in stage IC 5 (100.0%) cases had positive and, in stage IIIC 4 (80.0%) out of 5 cases had positive. Also [16] showed that in thestageI, 2(5.6)cases with score 1and 4(11.1) cases with score 2.In stage II(N=12), 4(33.3)cases with score 2.In stageIII (N=17), 12(70.6) cases with score 2. However, [17] foundp53 expression in advanced stage (IIA to IVB) more common rather than early stage (IA to IIB) endometrial carcinoma(11)55% versus (3)15%; (p value=0.006). As well as [18] showedthatP53 overexpression in endometrial carcinoma in the stage I, 3(13%) cases out of 23 (74.1%), instage II, 4 (66.7%)out of 6 (19.4%) cases, in stage III 2 (100%) cases out of 2(6.5%) cases. As well as [19] found that in stage I, p53 expressionpositive in 11 (36.7%) cases ,in stage II,p53 expression positive in 3 (75.0%) cases ,in stage III,p53 expression positive appeared in all cases 4 (100%).
3.2:P53 expression and intensity in endometrial cancer according grading
According to grading, p53 expression was reported in:7(41.2%) of grad I out of 17 cases, 5(55.5%) of grad II out of 9 cases, 2 (50%) of gradIIIout of 4 cases.Intensity of p53 expression in endometrial cancer showed that; in grad I, 10(58.8%) cases with score 0, 2(11.8%) cases with score +1, 3(17.6%) cases with score +2 ,2(11.8%) cases with score +3. While in grade II,4(44.4%) cases with score 0 ,0(0%) case with score +1, 3(33.3%) cases with score +2 , 2(22.2%) case with score +3.In grad III,2(50.0%) cases with score 0 ,0(0%) case with score +1 and +3, and 2(50.0%) cases with score +2. There were no significant to p53 expression and intensity in endometrial cancer according grading (P>0.05).According to grading, p53 expression was reported in:7(41.2%) of grad I out of 17 cases, 5(55.5%) of grad II out of 9 cases, 2 (50%) of gradIIIout of 4 cases.Intensity of p53 expression in endometrial cancer showed that; in grad I, 10(58.8%) cases with score 0, 2(11.8%) cases with score +1, 3(17.6%) cases with score +2, 2(11.8%) cases with score +3. While in grade II,4(44.4%) cases with score 0 ,0(0%) case with score +1, 3(33.3%) cases with score +2 , 2(22.2%) case with score +3.In grad III,2(50.0%) cases with score 0 ,0(0%) case with score +1 and +3, and 2(50.0%) cases with score +2. There were no significant to p53 expression and intensity in endometrial cancer according grading (P>0.05) Table (2). [19] showed that: ingrad I, 3(21.4%)caseswere positive expression for p53, ingrad II, 10(62.5%)cases were positive expression for p53 ,in grad III,5(62.5%) caseswere positive expression for p53. Moreover, [16] reported all cases in grade 1 were with score 0, 22(91.6%)cases out of 24 in grade II were score 0, 1(4.2%) case was with score +1 and +2,in grade III (N=23), 3(13.0%) cases were with score 0, 1(4.4%) cases was with score +1, 19(82.6%) cases were with score +2.Also [20] found thatp53 expression positive in 6 (6.8%) cases of grad I, ingrad II and grad III, 25(39.1%)cases were positive expression for p53.
3.3:
P53 expression and intensity in endometrial cancer according to muscle and lymph node invasiveness P53 expression and intensity in endometrial cancer according muscle invasiveness was reported among invasive endometrial cancer patients, 7 (50.0%) cases of them were found to be having p53 positive, while 7 (43.8%) cases of non-invasive were found to be p53 positive. Appreciation of p53 expression intensity in endometrial cancer in relation to invasiveness of tumor revealed that; in the invasive tumors, 7 (50.0%) cases with score 0, 0(0%) case with score +1, 5 (35.7%) cases with score +2 and 2(14.3%) cases with score +3. While in the non-invasive tumors, 9 (56.3%) cases with score 0 , 2(12.5%) cases with scores +1 and +3, 3(18.8%) cases with score +2. There were no significant to p53 expression and intensity according muscle invasiveness (P>0.05) Table ( 3). Table( 3):P53 expression and intensity in endometrial cancer according to muscle invasiveness P>0.05,non-significant) ) ( (P >0.05,non-significant P53 expression and intensity in endometrial cancer according lymph node invasion was reported amonglymph node invasive endometrial cancer patients, 4(57.1%) cases of them were found to be p53 positive, while 10 (34.5%) cases of non-invasive cases were found to be p53 positive. Analysis of p53 expression intensity in endometrial cancer in relation tolymph node invasiveness of tumor revealed that; in the invasive tumors,3(42.9%)cases with score 0 ,0(0.0%) case with score +1, 3 (42.9%) cases with score +2, and 1(14.3%) case with score +3. While in the non-invasive tumors, 13(56.5%)cases with score 0, 2(8.7%) cases with score +2, 5(21.7%) cases with score +2, and 3(13.0%) cases with score +3.No significant relationship between p53 expression and intensity with lymph nodes invasiveness Table(4). Also our results showed no significant to p53 expression and intensity according to muscle and lymph node invasiveness (P>0.05) ( Table 3 and 4).Results of [19] showed in no myometrial invasion p53 expression was positive in 2 (33.3%) cases out of 6 , while in invasion < 50%, p53 expression was positive in 8 (47.1%) [20] showed that in less than half myometrial invasion, , p53 expression positive in 16 (13.9%) cases. While in more than half in invasive muscle,p53 expression positive in 15 (40.5%) cases. On the other hand, results of [14] found that in lymph node invasion p53expression positive in 5 cases out of 10, while innon-invasive p53 expression was positive in 11 out of30 cases. Moreover, [20] explained thatin lymph node invasionp53 expression positive in 7 (46.7%),while in non-invasive p53 expression positive in 20 (18.2%) . [21] reported thatp53 expression positive in patients with lymph nodes invasion were 3(23.1%) cases with score 0, 5 (38.5%) caseswith score +1, 3 (23.1%) cases with score+2, and 2(15.4%) cases with score +3.In addition.
3.4: P53 expression and intensity in endometrial cancer according histological type
Regarding to p53 expression according to histological cell types (Fig 1) , the results reported that 6(85.7%) out of 7 cases positive in papillary , 7(35.0%) out of 20 cases positive in endometriod,patients ofsquamous cell carcinoma(SCC)have not p53 expression ,and expression of p53 was positive in mucinous 1(100%)case. These results showedsignificantfor p53 expression in endometrial cancer according histological type (P<0.01).Intensity assessment of p53 expression in endometrial cancer according histological type showed that; in papillary 1(14.3%) case was scored 0, no cases with score +1, and highest percentage 4(57.1%) cases with score +2, and 2(28.6%)cases were scored +3. While in endometriod 13(65.0%) cases were scored 0, 2(10.0%)cases were scored +1,4(20.0%) cases were scored +2 , and 1(5.0%)case was scored +3.While in mucinous 1(100%) case showed score +3.These results showedno significantfor p53 intensityin endometrial cancer according histological type (P>0.05) Table (5). Our findings showedsignificantfor p53 expression in endometrial cancer according to histological type (P=0.01). Results of [16] found that p53 higher expression inendometrial serous carcinomas than endometriod carcinomas(P<0.001).Moreover, [22] reported that expression for p53 were seen in approximately 80% to 90% cases of serous carcinoma. Also, [23] showed that expression for p53 can be seen in endometriod adenocarcinomas (~10%) cases.Our results positivity expression for p53 were higher significant in papillary serous than endometriod carcinomas. .However, [24] were explained that immunohistochemical positive for p53 [25] showed that in mucinous tumors p53 mutation was rarely.
3.5: EGFR expression and intensity in endometrial cancer according to staging, grading, muscles and lymph nodes invasion and histological types
EGFR expression and intensity in endometrial cancer according stage was reported that EGFR expression was in: 11(68.8%) of stage I out of 16 cases, 7(70%) of stage II out of 10 cases, and 2 (50.0%) of stage III out of 4 cases, no cases were reported in stage IV. Intensity of EGFR expression in endometrial cancer showed that; in stage I, 5(31.3%) cases with score 0,1(6.3%)case with score +1 and 5(31.2%) cases were scored +2 and +3. In stage II,3(30.0%) cases with score 0 ,+1 and +3, 1(10.0%) case were scored +2.In stage III, 2(50.0%) cases were scored 0, 0(0%) case with score +1, 1(25.0%) case with score +2 and +3. While in stage IV, 0(0%) case with score 0,+1, +2 and +3. There were no significant to EGFR expression and intensity in endometrial cancer according stage (P>0.05) Table (6). Analysis of EGFR expression and intensity in endometrial cancer according to grading was reported that EGFR expression was in:11(64.7%) of grad I out of 17 cases, 6(66.7%) of grad II out of 9 cases, 3 (75%) of gradIIIout of 4 cases.Intensity of EGFR expression in endometrial cancershowed that; in grad I, 6(35.3%)cases with score 0,1(5.9%) case with score +1,4(23.5%) cases were score +2 ,6(35.3%) cases with score +3.While in grade II,3(33.3%) cases with score 0, 2(22.2%) case with score +1,+2 and +3. Ingrad III,1(25.0%)case with score 0, +1, +2 and +3. There were no significant to EGFR expression and intensity in endometrial cancer according grading (P>0.0)Table (7). EGFR expression and intensity in endometrial cancer according muscle invasiveness was found that among invasive endometrial cancer patients, 10(71.4%) cases of them were found to be EGFR positive, while 10 (62.5%) cases of non-invasive cases were found to be EGFR positive. Appreciation of EGFR expression intensity in endometrial cancer tumors in relation to invasiveness of tumor revealed that; in the invasive tumors,4(28.5%) cases with score 0,2(14.3%) cases with score +1, 4 (28.6%) cases with score +2 and +3. While in the non-invasive tumors , 6(37.5%) cases with score 0, 2(12.5%) cases with score +1, 3(18.7%) cases with score +2 ,and 5(31.3%) cases with score +3.There were no significant to EGFR expression and intensity in endometrial cancer according muscle invasiveness (P>0.05) EGFR expression and intensity in endometrial cancer according lymph node invasionwas reported that among lymph node invasive endometrial cancer patients,4(57.1%) cases of them were found to be EGFR positive, while 16 (69.6%) cases of non-invasive cases were found to be EGFR positive. Appreciation of EGFR expression intensity in endometrial cancer tumors in relation to lymph node invasiveness of tumor revealed that; in the invasive tumors,3(42.9%) cases with score 0 ,2(28.5%) cases with score +1, 1 (14.3%) cases with score +2 and 3. While in the non-invasive tumors, 7(30.4%) cases with score 0, 2 (8.7%) cases with score +1, 6 (26.0%) cases with score +2 and 8 (34.8%) cases with score +3. There were no significant to EGFR expression and intensity in endometrial cancer according lymph node invasion (P>0.05) Table (9) . Expression of EGFR reported positive in 2(%28.6) out of 7 cases of papillary, and positive in 15(75.0%) out of 20 cases of endometriod, all patients 2(%100)cases withsquamous cell carcinoma(SCC) and mucinous 1(100%) case were appeared positiveforEGFR expression.Intensity assessment of EGFR expression in endometrial cancer according histological type showed that; in papillary 5(71.4%) cases were scored 0, 0(0%) case was scored +1, 1(14.3%) case was scored +2 and +3. While in endometriod 5(25.0%) cases were scored 0 and +2, 4(20.0%)cases were scored +1,5(33.3%) cases were scored +2 , and 6(30.0%)cases were scored +3, allsquamous cell carcinoma 2(%100) cases were scored +3. In mucinous, the case (100%) was scored +2. There were no significant toEGFR expression and intensity of in endometrial cancer according histological type (P>0.05) Table  ( Our results found no significant to EGFR expression and intensity according to all pathological parameters, staging, grading, muscles and lymph nodes invasion and histological types (P>0.05) ( Table 6 ,7,8,9 and 10). [28] reported thatEGFR expression positive were (22) cases in stage II ,while in stage III were positive (18) cases.In addition [29] explained that expression for EGFR in normal endometrial membrane and its overexpression is linked with the stage of endometrial cancer and a poor prognosis . Overexpression for EGFR in endometrial cancer is the important member of ErbB/HER receptor tyrosine kinase family, which has been showed to contributed in the development of human cancer [34] .Results of [28] found in grade I(n=29),EGFRexpression positive was in (18) cases and negative (11) ,ingrade IIand grade III(n=27),EGFR expression positive were in (22) cases.Moreover, [12] reported that EGFR expression positive were in 28(55.0%) cases out of 51 in gradeI, 23(44.0%) cases out of 52 in grade II, 45(33.0%) cases out of 138 in gradeII. In addition [26] EGFR protein was highly expressed in low grade( grade I and grade II) and high grade in endometriod carcinoma,this is due to EGFR intermediates the activation of intracellular signaling pathways, resulting in promoted proliferation and cell survival in endometriod carcinoma cells, together with these results enhanced more the importance of EGFR in the proliferation of low grade in endometriod tumor [26] .Also, [27] reported that positive expression for EGFR in the G III endometrial carcinoma tissues was significantly higher than that in grade I( P < 0.01), as well as found significant between GI and GII (P < 0.05).Moreover, our results showed no significant to EGFR expression and intensity according muscle and lymph node invasiveness(P>0.05. Results of [27] found thatthe positive expression for EGFR in the > 1/2 myometrial invasion group was higher than that in the ≤ 1/2 myometrial invasion group (P < 0.01). In addition, [30] explained that the myometrial invasion was (8) cases in internal half of the thickness of the myometrium, while (3) cases in the invasion was present in half of its external layer. On the other hand, results of [31] found that 165 patients were having negative lymph nodes and 38having positive lymph nodes out of 203 withendometrial cancer and showed the genes specified to be independently related with lymph node metastasis alsodepth of myometrial invasion was the single clinicopathological parameter to be independently related with lymph node metastasis. In addition [32] explained that highly expression for EGFR in the metastatic lymph node was linked with comparatively poor survival and give added risk of death.Moreover, [27] reported thatthe expression of EGFR had no correlation with the FIGO stage and the lymph node metastasis of endometrial carcinoma. However,our results showed no significant toEGFR expression and intensity in endometrial cancer according histological type (P>0.05.Results of [12] found that EGFR expression was lower in type II(34%) compared with type I EC (46%) and reported that EGFR expression positive in 60(46%)cases endometriod out of 130 and 36(36%) cases uterine serous papillary out of 101. [33] explain that EGFR expression was found in 60 (59.4%)cases out of 101 ofsquamous cell carcinoma. Our findings explain clearly, that the development and progression of endometrial cancer did not affected by p53 and EGFR expression; also these results need other confirmations.
IV.

Conclusion
In conclusion, the present study confirms that development and progression of the endometrial carcinoma does not depend on, histopathological variables (stage, grade, and depth of muscle and lymph nodes invasiveness.
